NeoGenomics, Inc. completed the acquisition of Trapelo Health for $65.4 million.
April 06, 2021
Share
NeoGenomics, Inc. (NasdaqCM:NEO) agreed to acquire Trapelo Health for $65 million on March 24, 2021. The consideration consists of $35 million in cash on hand and $30 million in NeoGenomics common stock is subject to satisfaction of certain customary closing conditions. Trapelo employees will join NeoGenomics. The transaction is expected to close in April 2021.
NeoGenomics, Inc. (NasdaqCM:NEO) completed the acquisition of Trapelo Health for $65.4 million on April 7, 2021. The purchase price consisted of (i) cash consideration of $35.6 million, which included a net adjustment of $0.6 million for estimated cash on hand of Trapelo and estimated working capital adjustments on the Trapelo Acquisition Date, and (ii) equity consideration consisting of 597,712 shares of NeoGenomics' common stock, with cash acquired as $0.713 million. The consideration is subject to satisfaction of certain customary closing conditions.
NeoGenomics, Inc. provides a range of oncology diagnostic testing and consultative services which includes technical laboratory services. The Company offers professional interpretation of laboratory test results by licensed physicians who specialize in pathology and oncology. Its segments include Clinical Services and Advanced Diagnostics. The Clinical Services segment consists of clinical cancer testing; interpretation and consultative services; molecular and NGS testing, and comprehensive technical and professional services offering. Its Clinical Services customers include community-based pathology and oncology practices, hospital pathology labs, reference labs, and academic centers. The Advanced Diagnostics segment consist of clinical trials and research, validation laboratory services, and informatics. Its Advanced Diagnostics customers include pharmaceutical companies to whom it provides testing and other services to support their research studies and clinical trials.
NEOGENOMICS, INC. 
